Mental Health and Substance Use Among Adults with Disabilities During the COVID-19 Pandemic — United States, February–March 2021
Weekly / August 27, 2021 / 70(34);1142–1149
Mark É. Czeisler1,2,3,4; Amy Board, DrPH5,6,7; JoAnn M. Thierry, PhD5; Charles A. Czeisler, PhD, MD1,3,4; Shantha M.W. Rajaratnam, PhD1,2,3,4; Mark E. Howard, MBBS, PhD1,2,8; Kristie E.N. Clarke, MD5 (View author affiliations)View suggested citation
What is already known about this topic?
Adults with disabilities experience higher levels of mental health conditions and substance use than do adults without disabilities.
What is added by this report?
During February–March 2021, 64.1% of surveyed U.S. adults with disabilities reported adverse mental health symptoms or substance use; past-month substance use was higher than that among adults without disabilities (40.6% versus 24.5%, respectively). Among adults with a diagnosis of mental health or substance use conditions, adults with disabilities more frequently (43% versus 35%) reported pandemic-related difficulty accessing related care and medications.
What are the implications for public health practice?
During public health emergencies, including the COVID-19 pandemic, enhanced mental health and substance use screening among adults with disabilities and improved access to related health care services are critical.
Views equals page views plus PDF downloads
Adults with disabilities, a group including >25% of U.S. adults (1), experience higher levels of mental health and substance use conditions and lower treatment rates than do adults without disabilities* (2,3). Survey data collected during April–September 2020 revealed elevated adverse mental health symptoms among adults with disabilities (4) compared with the general adult population (5). Despite disproportionate risk for infection with SARS-CoV-2, the virus that causes COVID-19, and COVID-19–associated hospitalization and mortality among some adults with disabilities (6), information about mental health and substance use in this population during the pandemic is limited. To identify factors associated with adverse mental health symptoms and substance use among adults with disabilities, the COVID-19 Outbreak Public Evaluation (COPE) Initiative† administered nonprobability–based Internet surveys to 5,256 U.S. adults during February–March 2021 (response rate = 62.1%). Among 5,119 respondents who completed a two-item disability screener, nearly one third (1,648; 32.2%) screened as adults with disabilities. These adults more frequently experienced symptoms of anxiety or depression (56.6% versus 28.7%, respectively), new or increased substance use (38.8% versus 17.5%), and suicidal ideation (30.6% versus 8.3%) than did adults without disabilities. Among all adults who had received a diagnosis of mental health or substance use conditions, adults with disabilities more frequently (42.6% versus 35.3%; p <0.001) reported that the pandemic made it harder for them to access related care or medication. Enhanced mental health and substance use screening among adults with disabilities and improved access to medical services are critical during public health emergencies such as the COVID-19 pandemic.
During February 16–March 8, 2021, among 8,475 eligible invited respondents aged ≥18 years, 5,261 (62.1%) completed nonprobability based, English-language, Internet-based Qualtrics surveys for COPE.§ Participants provided informed consent electronically. Quota sampling and survey weighting were used to match U.S. Census Bureau’s 2019 American Community Survey adult U.S. population estimates for sex, age, and race/ethnicity to enhance the representativeness of this nonrandom sample.
Among 5,256 respondents who answered questions for weighting variables, 5,119 (97.4%) completed a two-question disability screener.¶ Respondents completed clinically validated self-screening instruments for symptoms of anxiety and depression** and reported past-month new or increased substance use to cope with stress or emotions and serious suicidal ideation.†† Respondents also indicated prepandemic and past-month use of seven classes§§ of substances to cope with stress or emotions. Adults with diagnosed anxiety, depression, posttraumatic stress disorder, or substance use disorders indicated whether their ability to access care or medications for these conditions was easier, harder, or unaffected because of the pandemic. Prevalence estimates for adverse mental health symptoms and substance use were compared among adults with and without disabilities using chi-square tests. Multivariable Poisson regression models with robust standard error estimators were used to estimate adjusted prevalence ratios (aPRs) by symptom type among adults with and without disabilities. To calculate associations between disability status and adverse mental health symptoms or substance use over time, aPRs were estimated for symptoms among unique participants in previous COPE survey waves (June, September, and December 2020). Covariates¶¶ included sex, age group, race/ethnicity, income, U.S. Census region, urbanicity, and parental or unpaid caregiving roles.*** McNemar’s test assessed prepandemic and past-month substance use among adults with and without disabilities. Analyses were conducted using Python software (version 3.7.8; Python Software Foundation) and R statistical software (version 4.0.2; R Foundation) using the R survey package (version 3.29; R Foundation). The Monash University Human Research Ethics Committee reviewed and approved the study. This activity was reviewed by CDC and conducted consistent with applicable federal law and CDC policy.†††
Among a total of 5,119 respondents, 1,648 (32.2%) respondents reported living with disabilities (778 [47.2%] with limiting physical, mental, or emotional conditions only; 171 [10.4%] with health conditions requiring special equipment only; and 669 [42.4%] with both types of conditions) (Table). Overall, 64.1% of adults with disabilities reported adverse mental health symptoms or substance use compared with 36.0% of adults without disabilities; past-month substance use was higher among adults with disabilities (40.6%) than among adults without disabilities (24.5%). Prevalence estimates of each of the following were higher among adults with disabilities than among adults without disabilities: symptoms of anxiety or depression (56.6% versus 28.7%, respectively), new or increased substance use (38.8% versus 17.5%), and serious suicidal ideation (30.6% versus 8.3%) (Supplementary Table, https://stacks.cdc.gov/view/cdc/108999). At all timepoints, aPRs for all symptom types were significantly higher among adults with disabilities than among adults without disabilities (Figure 1). During February 16–March 8, 2021, among adults with disabilities, aPRs for symptoms of anxiety or depression and new or increased substance use were approximately 1.5 times as high, and the aPR for serious suicidal ideation was approximately 2.5 times as high as in adults without disabilities. Comparing subgroups of adults with and without disabilities, symptoms of anxiety or depression were approximately twice as prevalent among adults with disabilities who were aged ≥50 years (aPR = 2.4; 95% confidence interval [CI] = 1.7–3.2), those of non-Hispanic Asian race/ethnicity (2.4; 95% CI = 1.3–4.8), those of Hispanic or Latino (Hispanic) ethnicity (2.1; 95% CI = 1.4–3.0), and those who were not in parental or caregiver roles (2.1; 95% CI = 1.7–2.6). New or increased substance use was approximately twice as prevalent among adults with disabilities in parental roles only (2.4; 95% CI = 1.5–3.9) and among essential workers (2.3; 95% CI = 2.0–2.7). Suicidal ideation was also more prevalent among adults with disabilities aged ≥50 years (4.0; 95% CI = 2.1–7.8), those of Hispanic ethnicity (3.4; 95% CI = 1.9–6.0), adults in unpaid caregiving roles (3.4; 95% CI = 1.5–7.7), and essential (3.5; 95% CI = 2.8–4.4) or nonessential (5.3; 95% CI = 2.8–10.1) workers.
The prevalence of substance use to cope with stress or emotions among adults with disabilities was higher than that among adults without disabilities, both prepandemic (39.7% versus 25.3%, respectively) and in the past month (40.6% versus 24.5%; both p<0.001) (Figure 2). Among adults with disabilities, the past-month prevalence of methamphetamine use (8.4%), nonopioid prescription drug misuse (4.9%), and polysubstance use (16.9%) was approximately twice as high, and the prevalence of cocaine use (6.4%) and prescription or illicit opioid use (9.1%) were nearly three times as high compared with those among adults without disabilities (methamphetamine use 3.4%; nonopioid prescription drug misuse 2.0%; polysubstance use 7.9%; cocaine use 2.2%; prescription or illicit opioid use 3.2%). Past-month methamphetamine use prevalence increased significantly compared with prepandemic use prevalence among all respondents (with disabilities, 45.6% increase, p<0.001; without disabilities, 40.6% increase, p = 0.003). Among respondents who reported a diagnosed mental health or substance use condition, a higher percentage of adults with (versus without) disabilities reported that accessing care or medication was harder because of the COVID-19 pandemic (42.6% versus 35.3%, respectively, p<0.001).
Nearly two thirds of surveyed adults with disabilities (who represented approximately 32% of the sample) reported adverse mental health symptoms or substance use in early 2021, compared with approximately one third of adults without disabilities. Serious suicidal ideation was approximately 2.5 times as high among adults with disabilities, and methamphetamine use, opioid use, nonopioid prescription drug misuse, and polysubstance use were at least twice as prevalent among adults with disabilities. These findings suggest value in enhanced mental health screening among adults with disabilities and in ensuring accessibility of routine and crisis services, particularly given that many adults reported that the COVID-19 pandemic had reduced mental health and substance use care or medication accessibility. Mental health disparities among adults with disabilities were observed across demographic groups, highlighting the importance of ensuring access to disaster distress§§§ and suicide prevention¶¶¶ resources in this population. Important strategies to prevent persons from becoming suicidal include strengthening economic supports, promoting connectedness, and teaching coping skills.**** Health care providers could incorporate trauma-informed care, because adults with disabilities might have encountered stigma and trauma in previous health care interactions. Adults with disabilities more frequently reported prepandemic and past-month substance use to cope with stress or emotions compared with adults without disabilities. The substance with the largest increase in use was methamphetamine, which is particularly concerning given the increase in amphetamine overdoses†††† (7). Drug overdose deaths rose in 2020, driven by synthetic opioids.§§§§ Consistent with previous research, adults with disabilities disproportionately reported opioid use and nonopioid prescription drug misuse (8), highlighting the importance of educating patients and ensuring clinician access to prescription drug monitoring programs.¶¶¶¶ Nearly one in ten adults with disabilities reported past-month opioid use, and opioid use among adults without disabilities increased. Policies that reduce barriers to evidence-based treatment, including recently updated buprenorphine practice guidelines,***** might improve access.
The findings in this report are subject to at least four limitations. First, self-reported mental health and substance use might be subject to social desirability biases and stigma, which could lead to underreporting. Second, because the surveys were English-language only and data were obtained using nonprobability–based sampling, despite quota sampling and survey weighting, the findings from this nonrandom sample might not be generalizable. However, the proportion and demographics of surveyed adults with disabilities were similar to those of recent samples from other sources with the same or similar screening questions (1,2,4), and prevalence estimates of symptoms of anxiety and depression were largely consistent with those from other sources for the U.S. adult population (9) and adults with disabilities (4) including the U.S. Census Bureau’s probability-based Household Pulse Survey (64.3% among adults with disabilities compared with 27.4% among adults without disabilities in April 2021).††††† Third, the respondents with disabilities might not be representative of all adults with disabilities, some of whom might lack access to hardware or assistive technologies required to independently complete the survey. Finally, adverse mental health symptoms might, in some cases, represent respondents’ disabling mental health conditions, which could confound associations with other comorbid disabling conditions (e.g., physical, cognitive, sensory); however, sensitivity analyses excluding adults with disabilities who had mental health or substance use diagnoses yielded consistent findings.
Adults with disabilities have been disproportionately affected by adverse mental health symptoms and substance use during the COVID-19 pandemic, highlighting the importance of improved access to treatment for this population. Clinicians might consider screening all patients for mental health and substance use conditions during and after the pandemic.§§§§§ Behavioral health care providers might also consider facility, policy, and procedural pathway analyses to ensure accessibility for clients with physical, sensory, or cognitive disabilities.¶¶¶¶¶ Strategies designed to increase access to care and medication during public health emergencies, such as telehealth, might consider telemedicine platform and system accessibility for adults with disabilities (10); further research to identify and address health disparities among adults with disabilities could help guide additional evidence-based strategies.
Survey respondents; Mallory Colys, Sneha Baste, Daniel Chong, Rebecca Toll, Qualtrics, LLC; Rebecca Robbins, Matthew D. Weaver, Laura K. Barger, Brigham and Women’s Hospital and Harvard Medical School; Elise R. Facer-Childs, Joshua F. Wiley, Monash University; Rashon I. Lane, CDC; CDC Foundation; BNY Mellon; Hopelab, Inc.; The Kinghorn Foundation; Australian-American Fulbright Commission.
Corresponding author: Amy Board, email@example.com.
1Turner Institute for Brain and Mental Health and School of Psychological Sciences, Monash University, Melbourne, Australia; 2Austin Health, Melbourne, Australia; 3Brigham and Women’s Hospital, Boston, Massachusetts; 4Harvard Medical School, Boston, Massachusetts; 5CDC COVID-19 Response Team; 6National Center for Injury Prevention and Control, CDC; 7Epidemic Intelligence Service, CDC; 8University of Melbourne, Melbourne, Australia.
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Charles A. Czeisler reports an institutional grant paid to Monash University from the CDC Foundation (funding provided by BNY Mellon); an institutional grant to Monash University from WHOOP, Inc.; being the incumbent of an endowed professorship provided to Harvard Medical School by Cephalon, Inc. in 2004; institutional support for Quality Improvement Initiative from Delta Airlines and Puget Sound Pilots; education/research support from Jazz Pharmaceuticals PLC, Inc., Philips Respironics, Inc., Regeneron Pharmaceuticals, and Sanofi S.A.; educational grant funding from ResMed, Teva Pharmaceuticals Industries Ltd., Australia and Vanda Pharmaceuticals, Inc.; royalty payments from Philips Respironics, Inc. on sales of the Actiwatch-2 and Actiwatch-Spectrum devices; personal consultancy and lecture fees from Physician’s Seal, LLC, State of Washington Board of Pilotage Commissioners, Vanda Pharmaceuticals, Inc., Teva Pharmaceutical Industries, Ltd, Australia, Tencent Holdings, Ltd, and the National Sleep Foundation (Chair, Sleep Timing and Variability Consensus Panel); payment for expert witness testimony related to matters involving Aegis Chemical Solutions, Amtrak, Casper Sleep, Inc., Enterprise Rent-A-Car, Dallas Police Association, FedEx, PAR Electrical Contractors, Inc., Puget Sound Pilots, Schlumberger Technology Corp., Union Pacific Railroad, United Parcel Service, and Vanda Pharmaceuticals, Inc.; travel support from Tencent Holdings, Ltd., Aspen Brain Institute, Bloomage International Investment Group, Inc., Stanley Ho Medical Development Foundation, German National Academy of Sciences, National Safety Council, and the National Sleep Foundation; membership AARP advisory board, Children and Screens: Institute of Digital Media and Child Development, Klarman Family Foundation, and Biotechnology and Biological Sciences Research Council (U.K.); equity interest in Vanda Pharmaceuticals, Inc.; and institutional educational gifts to Brigham and Women’s Hospital from Johnson & Johnson and Harmony Biosciences, LLC. Mark É. Czeisler reports institutional grants paid to Monash University from the CDC Foundation (funding provided by BNY Mellon), and from WHOOP, Inc.; funding from the Australian-American Fulbright Foundation (funding provided by the Kinghorn Foundation); and personal consultancy fees from Vanda Pharmaceuticals, Inc. Mark E. Howard and Shantha M.W. Rajaratnam report institutional grants paid to Monash University from the CDC Foundation (funding provided by BNY Mellon), and from WHOOP, Inc. Shantha M.W. Rajaratnam reports an institutional grant paid to Monash University from the Cooperative Research Centre for Alertness, Safety and Productivity; consulting fees paid to Monash University from Teva Pharmaceutical Industries, Ltd, Australia and Ukraine, Vanda Pharmaceuticals, Inc., BHP Billiton, and Herbert Smith Freehils; patent PTC/AU2021/050126 for Systems and Methods for Monitoring and Control of Sleep Patterns; and institutional consultancy fees from Circadian Therapeutics. No other potential conflicts of interest were disclosed.
† The COVID-19 Outbreak Public Evaluation (COPE) Initiative (https://www.thecopeinitiative.org/external icon) is designed to assess public attitudes, behaviors, and beliefs related to COVID-19 pandemic and to evaluate mental and behavioral health during the pandemic. The COPE Initiative surveys included in this analysis were administered by Qualtrics, LLC (https://www.qualtrics.comexternal icon), a commercial survey company with a network of participant pools with varying recruitment methodologies that include digital advertisements and promotions, word-of-mouth and membership referrals, social networks, television and radio advertisements, and offline mail-based approaches.
§ Eligibility to complete surveys was determined after electronic contact of potential participants with inclusion criteria of age ≥18 years and residence within the United States.
¶ Disability was defined as such based on a qualifying response by an adult to either one of two questions: “Are you limited in any way in any activities because of physical, mental, or emotional condition?” and “Do you have any health conditions that require you to use special equipment, such as a cane, wheelchair, special bed, or special telephone?” https://www.cdc.gov/brfss/questionnaires/pdf-ques/2015-brfss-questionnaire-12-29-14.pdfpdf icon
** Symptoms of anxiety and depression were assessed with the four-item Patient Health Questionnaire (PHQ-4). Respondents who scored ≥3 out of 6 on the Generalized Anxiety Disorder (GAD-2) and Patient Health Questionnaire (PHQ-2) subscales were considered symptomatic for the respective conditions.
†† New or increased substance use was assessed with the question, “Have you started or increased using substances to help you cope with stress or emotions during the COVID-19 pandemic? Substance use includes alcohol, legal or illegal drugs, or prescription drug use in any way not directed by a doctor.” Suicidal ideation was assessed with an item from the National Survey on Drug Use and Health (https://nsduhweb.rti.org/respweb/homuepage.cfmexternal icon) adapted to refer to the preceding 30 days, “At any time in the past 30 days, did you seriously think about trying to kill yourself?”
§§ Alcohol, marijuana, cocaine, methamphetamine, prescription or illicit opioids, benzodiazepines, and prescription drugs other than opioids used in a way not directed by a doctor.
¶¶ Models to estimate aPRs for adverse mental health symptoms and substance use were run with each of the collinear variables income and education during preliminary analysis. Estimated aPRs did not differ meaningfully. In the report, the models including income were included to account for potential differences in access to health care more directly. To avoid collinearity with age, employment status was included in a separate model, and aPRs were not estimated for retired status or student employment status.
*** Adults who were in parental or unpaid caregiving roles were self-identified. For this analysis, the definition of unpaid caregivers of adults was having provided unpaid care to a relative or friend aged ≥18 years to help them take care of themselves at any time during the three months before the survey. The definition of someone in a parental role was having provided unpaid care to a relative or friend aged <18 years. Respondents were categorized as being in a parental role only, a caregiver of adults role only, having both parental and caregiving roles, or having neither parental nor caregiving roles. Adults in parenting roles might not have been biologic or adoptive parents of the children.
††† 45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. Sect. 241(d); 5 U.S.C. Sect. 552a; 44 U.S.C. Sect. 3501 et seq.
§§§ Substance Abuse and Mental Health Services Administration National Helpline (https://www.samhsa.gov/find-help/national-helplineexternal icon); Disaster Distress Helpline (https://www.samhsa.gov/disaster-preparednessexternal icon).
¶¶¶ National Suicide Prevention Lifeline: 1–800–273-TALK for English, 1–888–628–9454 for Spanish, or Lifeline Crisis Chat (https://suicidepreventionlifeline.org/chat/external icon).
§§§§§ https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/drug-use-illicit-screeningexternal icon; https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/depression-in-adults-screeningexternal icon
- Okoro CA, Hollis ND, Cyrus AC, Griffin-Blake S. Prevalence of disabilities and health care access by disability status and type among adults—United States, 2016. MMWR Morb Mortal Wkly Rep 2018;67:882–7. https://doi.org/10.15585/mmwr.mm6732a3external icon PMID:30114005external icon
- Cree RA, Okoro CA, Zack MM, Carbone E. Frequent mental distress among adults, by disability status, disability type, and selected characteristics—United States, 2018. MMWR Morb Mortal Wkly Rep 2020;69:1238–43. https://doi.org/10.15585/mmwr.mm6936a2external icon PMID:32914770external icon
- Okoro CA, McKnight-Eily LR, Strine TW, Crews JE, Holt JB, Balluz LS. State and local area estimates of depression and anxiety among adults with disabilities in 2006. Disabil Health J 2011;4:78–90. https://doi.org/10.1016/j.dhjo.2010.05.001external icon PMID:21419371external icon
- Okoro CA, Strine TW, McKnight-Eily L, Verlenden J, Hollis ND. Indicators of poor mental health and stressors during the COVID-19 pandemic, by disability status: a cross-sectional analysis. Disabil Health J 2021;101110:101110. https://doi.org/10.1016/j.dhjo.2021.101110external icon PMID:33962896external icon
- Czeisler MÉ, Lane RI, Wiley JF, Czeisler CA, Howard ME, Rajaratnam SMW. Follow-up survey of US adult reports of mental health, substance use, and suicidal ideation during the COVID-19 pandemic, September 2020. JAMA Netw Open 2021;4:e2037665. https://doi.org/10.1001/jamanetworkopen.2020.37665external icon PMID:33606030external icon
- Gleason J, Ross W, Fossi A, Blonsky H, Tobias J, Stephens M. The devastating impact of Covid-19 on individuals with intellectual disabilities in the United States. NEJM Catalyst [Commentary] 2021. https://catalyst.nejm.org/doi/full/10.1056/CAT.21.0051external icon.
- Liu S, Scholl L, Hoots B, Seth P. Nonfatal drug and polydrug overdoses treated in emergency departments—29 states, 2018–2019. MMWR Morb Mortal Wkly Rep 2020;69:1149–55. https://doi.org/10.15585/mmwr.mm6934a1external icon PMID:32853194external icon
- Lauer EA, Henly M, Brucker DL. Prescription opioid behaviors among adults with and without disabilities—United States, 2015–2016. Disabil Health J 2019;12:519–22. https://doi.org/10.1016/j.dhjo.2018.12.001external icon PMID:30594480external icon
- Vahratian A, Blumberg SJ, Terlizzi EP, Schiller JS. Symptoms of anxiety or depressive disorder and use of mental health care among adults during the COVID-19 pandemic—United States, August 2020–February 2021. MMWR Morb Mortal Wkly Rep 2021;70:490–4. https://doi.org/10.15585/mmwr.mm7013e2external icon PMID:33793459external icon
- Annaswamy TM, Verduzco-Gutierrez M, Frieden L. Telemedicine barriers and challenges for persons with disabilities: COVID-19 and beyond. Disabil Health J 2020;13:100973. https://doi.org/10.1016/j.dhjo.2020.100973external icon PMID:32703737external icon
FIGURE 1. Adjusted prevalence ratios* and 95% confidence intervals† for ≥1 symptoms of adverse mental health or substance use (A), symptoms of anxiety or depression (B), new or increased substance use (C), and suicidal ideation (D) among adults with disabilities, compared with adults without disabilities (referent group)§ — United States, February 16–March 8, 2021¶
Abbreviations: aPR = adjusted prevalence ratio; CI = confidence interval.
* With 95% CIs indicated by error bars. Multivariable Poisson regression models included sex, age group in years, race/ethnicity, income, U.S. Census region, urbanicity, and parental or unpaid caregiving roles (parental roles were not assessed in June 2020; only unpaid caregiving roles were considered for this variable in the June 2020 models). Separate, additional models were run to estimate aPRs for the following employment statuses: essential worker, nonessential worker, and unemployed. Estimates were not made for retired or student employment statuses because of collinearity between these employment statuses and age.
† For panels A, B, and C, the y-axis range for aPR estimates is 0–5, which contains all aPRs and 95% CIs for these panels with maximal view of differences in model estimates. For panel D, given the relative rarity of suicidal ideation among some demographic subgroups that results in wide CIs for aPR estimates, the y-axis range is 0–10.
§ Within each subgroup, adults without disabilities are the reference group used to estimate aPRs for outcomes among adults with disabilities.
¶ Estimated aPRs are during February 16–March 8, 2021, except for the “over time” estimates, which also include estimates based on data collected during June 24–30, 2020, August 28–September 6, 2020, and December 6–27, 2020.
FIGURE 2. Prevalence of prepandemic and past-month substance use to cope with stress or emotions among adults, by disability status and type of substance — United States, February 16–March 8, 2021*,†,§
* Overall, prepandemic and past-month use of any of these substances were reported by 39.7% and 40.6%, respectively, of adults with disabilities, and by 25.3% and 24.5%, respectively, of adults without disabilities.
† All differences between adults with disabilities and adults without disabilities were significant (chi-square p-value <0.05).
§ Circles for use of marijuana (among adults with disabilities), use of prescription drugs (among adults without disabilities), and polysubstance use (among adults with disabilities) might appear overlapping because of very small changes in reported prevalence (<1% in all cases).
Suggested citation for this article: Czeisler MÉ, Board A, Thierry JM, et al. Mental Health and Substance Use Among Adults with Disabilities During the COVID-19 Pandemic — United States, February–March 2021. MMWR Morb Mortal Wkly Rep 2021;70:1142–1149. DOI: http://dx.doi.org/10.15585/mmwr.mm7034a3external icon.
MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.
All HTML versions of MMWR articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (https://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables.
Questions or messages regarding errors in formatting should be addressed to firstname.lastname@example.org.